The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial - Thazhath, Sony S.; Marathe, Chinmay S.; Wu, Tongzhi; Chang, Jessica; Khoo, Joan; Kuo, Paul; Checklin, Helen L.; Bound, Michelle J.; Rigda, Rachael S.; Crouch, Benjamin; Jones, Karen L.; Horowitz, Michael; et al. (Diabetes (New York, N.Y.), 2016)
Keywords: Adult; Case-Control Studies; Cross-Over Studies; Diabetes; Diabetes Mellitus, Type 2 - metabolism; Double-Blind Method; Duodenum - drug effects; Duodenum - metabolism; Female; Gastric Emptying - drug effects; Gastrointestinal Motility - drug effects; Gastrointestinal Transit - drug effects; Glucagon-Like Peptide-1 Receptor - agonists; Glucose; Glucose - metabolism; Healthy Volunteers; Humans; Hypoglycemic Agents - pharmacology; Intestine, Small - drug effects; Intestine, Small - metabolism; Male; Middle Aged; Nausea; Neuropeptides; Peptides - pharmacology; Small intestine; Venoms - pharmacology